Hasil Pencarian - Bilal Piperdi

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices

    Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices oleh Vamsidhar Velcheti, Xiaohan Hu, Bilal Piperdi, Thomas Burke

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model

    Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model oleh Elaine C. Maggi, Silvia Gravina, Haiying Cheng, Bilal Piperdi, Ziqiang Yuan, Xiao Dong, Steven K. Libutti, Jan Vijg, Jan Vijg, Jan Vijg, Cristina Montagna, Cristina Montagna

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

    Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 oleh Aaron S. Mansfield, MD, Roy S. Herbst, MD, PhD, Gilberto de Castro, Jr., MD, PhD, Rina Hui, MB, BS, PhD, Nir Peled, MD, PhD, Dong-Wan Kim, MD, Silvia Novello, MD, PhD, Miyako Satouchi, MD, Yi-Long Wu, MD, Edward B. Garon, MD, Martin Reck, MD, PhD, Andrew G. Robinson, MD, Ayman Samkari, MD, Bilal Piperdi, MD, Victoria Ebiana, MD, Jianxin Lin, MS, Tony S.K. Mok, MD

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC oleh Marina C. Garassino, MD, Shirish Gadgeel, MD, Silvia Novello, MD, PhD, Balazs Halmos, MD, Enriqueta Felip, MD, Giovanna Speranza, MD, Rina Hui, PhD, Edward B. Garon, MD, Hidehito Horinouchi, MD, PhD, Shunichi Sugawara, MD, PhD, Delvys Rodriguez-Abreu, MD, PhD, Martin Reck, MD, Razvan Cristescu, PhD, Deepti Aurora-Garg, PhD, Andrey Loboda, PhD, Jared Lunceford, PhD, Julie Kobie, PhD, Mark Ayers, MS, Bilal Piperdi, MD, M. Catherine Pietanza, MD, Luis Paz-Ares, MD, PhD

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: